蛋白质组学国际 获得了美国专利 ProprignerEso, 血液测试 以高精度检测早期食道癌。 Proteomics International got a U.S. patent for PromarkerEso, a blood test that detects early-stage esophageal cancer with high accuracy.

国际蛋白质组学组织获得了美国ProprignerEso专利,这是一项血液测试,通过分析蛋白质生物标志和临床因素,及早检测食道肾上腺癌(EAC)。 Proteomics International has received a U.S. patent for PromarkerEso, a blood test that detects esophageal adenocarcinoma (EAC) early by analyzing protein biomarkers and clinical factors. 非侵入性测试为昂贵的入侵内分泌镜提供了更简单的替代方法,在确定早期的EAC方面显示出很强的准确性,早期的EAC往往被诊断为晚期,存活率低于20%。 The non-invasive test offers a simpler alternative to costly, invasive endoscopies and has shown strong accuracy in identifying early-stage EAC, which is often diagnosed late with a survival rate below 20%. 这一专利有效期至2036年,用于诊断EAC和Barrett的食道,并在关键市场上扩大该公司的全球知识产权。 The patent, valid until 2036, covers use in diagnosing EAC and Barrett’s esophagus and expands the company’s global intellectual property in key markets. 发展支持商业化努力,以改善早期发现,降低保健费用,并随着东非共同体利率的上升而拯救生命。 The development supports commercialization efforts aimed at improving early detection, reducing healthcare costs, and saving lives as EAC rates rise.